FROM HOPE TO TREATMENTS
For families living with Hereditary Spastic Paraplegia (HSP) and Primary Lateral Sclerosis (PLS), research is more than something happening in a laboratory.
Research represents possibility.
- The possibility of understanding why a disease progresses.
- The possibility of identifying a biomarker that tells us whether a treatment is working.
- The possibility of finding an existing medication that can be repurposed.
- And ultimately, the possibility of developing treatments that can slow, stop, prevent, or reverse the effects of HSP and PLS.
2026 Has Been a Year of Building the Roadmap
This year, the Spastic Paraplegia Foundation has continued working to move HSP and PLS research closer to therapeutic development.
SPF is bringing researchers, clinicians, patients, families, regulatory experts, and research partners together around an increasingly important question: How do we move promising science toward treatments for patients?
That means looking beyond individual genes alone and identifying biological problems that may be shared across multiple forms of HSP and potentially PLS.
More details coming January 1, 2027!
